Clinical trials: Immunogenicity
SARS-CoV-2, Influenza
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old
The primary goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 compared to co-administered mRNA-1010 and mRNA-1273 vaccines and to the individual vaccines alone in healthy participants.
- Trial name
- NCT05375838
- Testing
- mRNA-1073, mRNA-1010, mRNA-1273
- Where
- 14 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Schistosomiasis
A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults
This is a Phase I, first-in-human study of a vaccine against S. mansoni infection.The study will recruit 72 healthy adult males and non-pregnant females from a single clinical center to test two formulations of Sm-TSP-2 vaccine…
- Trial name
- NCT02337855
- Testing
- Sm-TSP-2/Alhydrogel, Sm-TSP-2/Alhydrogel/GLA-AF
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Meningitis, Meningococcal
Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months
The purpose of this study is to evaluate the immunogenicity and safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in healthy volunteers aged from 3 to 5 months.
- Trial name
- NCT05252715
- Testing
- Meningococcal ACYW135 Polysaccharide Conjugate Vaccine, Meningococcal A and C Polysaccharide Conjugate Vaccine
- Where
- 2 sites in China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
COVID-19, COVID-19 Immunisation
Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults
This is a phase 1, open-label, randomized clinical trial in males and non-pregnant females, 18 years of age and older, who are in good health, have no known history of COVID-19 or SARS-CoV-2 infection, and meet all other…
- Trial name
- NCT04785144
- Testing
- mRNA-1273, mRNA-1273.351
- Where
- 4 sites in United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Botulism
Tolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG®
This Phase 2, open-label, uncontrolled study designed to evaluate safety, tolerability, and immunogenicity of a single dose of rBV A/B in healthy participants previously immunized with pentavalent botulinum toxoid (or pentavalent…
- Trial name
- NCT06112834
- Testing
- rBV A/B
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- California Department of Public Health
Flu, Human
Study of the Safety, Tolerability and Immunogenicity of an Intranasal Influenza Vaccine Administered to Healthy Adults
The objectives of this study were to assess the safety and tolerability of DCB07010 when given intranasally at escalating dose levels of 7.5μg, 15μg, 30μg and 45μg, in combination with 22.5μg of influenza HA antigen (7.5μg HA of…
- Trial name
- NCT03293732
- Testing
- DCB07010, HA antigens
- Where
- Taiwan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Advagene Biopharma Co. Ltd.
Staphylococcus Aureus, Bacteremia
Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2)
This study will assess the efficacy of a single dose of V710 vaccine to prevent serious Staphylococcus aureus infections following elective cardiothoracic surgery.
- Conditions
- Staphylococcus Aureus, Bacteremia, Mediastinitis
- Trial name
- NCT00518687
- Testing
- V710
- Volunteers
- 8,031 people
- Sponsor
- Merck Sharp & Dohme LLC
Norovirus
Recombinant, Bivalent, Norovirus Vaccine Study
This clinical study will evaluate the vaccine candidate rNV-2v, which is under development to prevent disease triggered by noroviruses. Noroviruses are one of the leading causes of gastrointestinal diseases in the world.
- Trial name
- NCT05508178
- Testing
- Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (100 µg), Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (300 µg)
- Where
- Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Icon Genetics GmbH
Tetanus, Diphtheria
DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants
Primary objective: To demonstrate the non-inferiority in terms of seroprotection rates (Hib antigen (PRP), Diphtheria, Tetanus, and Pertussis antigens (PT and FHA), and polio types 1, 2 and 3 antigens) of investigational arm…
- Conditions
- Tetanus, Diphtheria, Pertussis, Poliomyelitis
- Trial name
- NCT02274285
- Testing
- DTaP-IPV/Hib Combined vaccine, DTaP-IPV vaccine and Hib vaccine
- Where
- 12 sites in Japan
- Volunteers
- 424 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Encephalitis, Tick-Borne
Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years
blood draw five years after booster-immunization with TBE vaccine to investigate immunogenicity in children
- Trial name
- NCT00452621
- Testing
- blood draw
- Where
- 8 sites in Germany
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)
This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 S-OIV (swine flu) vaccine in healthy young children.
- Trial name
- NCT00972816
- Testing
- MF59-eH1N1
- Where
- 35 sites in United States, Mexico
- Volunteers
- 1,357 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
HIV Infections
Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults
The purpose of this study is to find out whether three different anti-HIV vaccines are safe and whether they help prevent HIV infection. These vaccines are called vCP205, vCP1433, and vCP1452.
- Trial name
- NCT00000904
- Testing
- ALVAC(2)120(B,MN)GNP (vCP1452), gp160 MN/LAI-2, ALVAC(1)120(B,MN)GNP (vCP1433)
- Where
- 6 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B
Comparison of Monodose and Multidose Presentations of GSK Biologicals' Hepatitis B Vaccine in Terms of Immune Response
GSK Biologicals' currently licensed multidose hepatitis B vaccine will be compared to the currently licensed monodose hepatitis B vaccine in a population with well documented hepatitis B immunological response to the vaccine…
- Trial name
- NCT00197158
- Testing
- Hepatitis B vaccine
- Where
- Belgium
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infectious Disease
Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine
A Phase Ⅲ clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 6 weeks)-5 years (before 6th birthday).
- Trial name
- NCT06617715
- Testing
- Sinovac PCV13, Prevnar®
- Where
- China
- Volunteers
- 3,080 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Rabies Human, Antibody Titer
Vaccine Prevention of Rabies Adopts 4-shot Immunization Method
A phase III clinical trial to evaluate the immunogenicity and safety of freeze-dried human rabies vaccine (Vero cell) developed by Changchun Zhuoyi Biological Co., Ltd. inoculated in a 4-dose procedure (2-1-1)
- Trial name
- NCT05549908
- Testing
- rabies vaccine
- Where
- China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Changchun Zhuoyi Biological Co., Ltd
Shigellosis, Bacillary Dysentery
Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)
This study is an open-label, dose-escalating Phase 1 investigation of S. flexneri 2a InvaplexAR vaccine. A total of up to 40 subjects will receive one of four S. flexneri 2a InvaplexAR vaccine doses.
- Trial name
- NCT02445963
- Testing
- Shigella flexneri 2a InvaplexAR
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Herpes Zoster
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
The purpose of this study is to evaluate the efficacy of GSK Biologicals' vaccine GSK1437173A in the prevention of Herpes zoster (HZ) in autologous haematopoietic cell transplant recipients 18 years of age and older.
- Trial name
- NCT01610414
- Testing
- Herpes Zoster vaccine GSK1437173A
- Where
- 178 sites in United States, Australia and 26 more
- Volunteers
- 1,877 people
- Sponsor
- GlaxoSmithKline
Chronic Spontaneous Urticaria
Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001
An open label extension (OLE) study offered to subjects with Chronic Spontaneous Urticaria that have completed the AK006-001 (NCT06072157) Part C referred to as the Main study portion of the study.
- Trial name
- NCT06577116
- Testing
- AK006 IV
- Where
- 14 sites in United States, Canada
- Volunteers
- 29 people
- Sponsor
- Allakos Inc.
Influenza
H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults
The purpose of this research study is to compare how the body reacts to different strengths of an H5N1 flu vaccine when given by different routes of injection (injection into the skin or into the muscle).
- Trial name
- NCT00310206
- Testing
- Inactivated Influenza A Vaccine A/H5N1
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diphtheria, Tetanus
Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older
Primary objective: To demonstrate that 3 doses of a vaccine containing Td-IPV valences administered in a 0, 1 and 6-month schedule induce an acceptable immune response in terms of seroprotection rates (SPR) against diphtheria…
- Conditions
- Diphtheria, Tetanus, Poliomyelitis, Pertussis
- Trial name
- NCT01287949
- Testing
- Diphtheria, tetanus, polio and pertussis vaccination
- Where
- 12 sites in France, Germany
- Volunteers
- 342 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company